192 related articles for article (PubMed ID: 1450492)
1. Therapeutic trials on progressive muscular dystrophy.
Satoyoshi E
Intern Med; 1992 Jul; 31(7):841-6. PubMed ID: 1450492
[TBL] [Abstract][Full Text] [Related]
2. [Effect of a cysteine protease inhibitor EST on urinary 3-methylhistidine in dystrophic hamsters (BIO 14.6)].
Terao T; Mashino K; Takatsu M; Hiraguchi M
Rinsho Shinkeigaku; 1986 Nov; 26(11):1218-23. PubMed ID: 3549099
[No Abstract] [Full Text] [Related]
3. Treatment of muscular dystrophies.
Kingston WJ; Moxley RT
Gen Pharmacol; 1989; 20(3):263-8. PubMed ID: 2663627
[TBL] [Abstract][Full Text] [Related]
4. Prolongation of life span of dystrophic hamster by cysteine proteinase inhibitor, loxistation (EST).
Tamai M; Omura S; Kimura M; Hanada K; Sugita H
J Pharmacobiodyn; 1987 Nov; 10(11):678-81. PubMed ID: 3482108
[TBL] [Abstract][Full Text] [Related]
5. Clinical investigation in Duchenne muscular dystrophy: IV. Double-blind controlled trial of leucine.
Mendell JR; Griggs RC; Moxley RT; Fenichel GM; Brooke MH; Miller JP; Province MA; Dodson WE
Muscle Nerve; 1984 Sep; 7(7):535-41. PubMed ID: 6399927
[TBL] [Abstract][Full Text] [Related]
6. [Experimental animal information file: effect of bestatin in muscular dystrophy in mice].
Kawamata J
Gan To Kagaku Ryoho; 1983 Nov; 10(11):2425-6. PubMed ID: 6639104
[No Abstract] [Full Text] [Related]
7. Successful treatment of murine muscular dystrophy with the protease inhibitor bestatin.
Tsuji S; Matsushita H
J Neurol Sci; 1986 Feb; 72(2-3):183-94. PubMed ID: 3711932
[TBL] [Abstract][Full Text] [Related]
8. The use of an extended baseline period in the evaluation of treatment in a longitudinal Duchenne muscular dystrophy trial.
Madsen KS; Miller JP; Province MA
Stat Med; 1986; 5(3):231-41. PubMed ID: 3526500
[TBL] [Abstract][Full Text] [Related]
9. Discovery of Novel Therapeutics for Muscular Dystrophies using Zebrafish Phenotypic Screens.
Widrick JJ; Kawahara G; Alexander MS; Beggs AH; Kunkel LM
J Neuromuscul Dis; 2019; 6(3):271-287. PubMed ID: 31282429
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic trials in muscular dystrophy. III. Studies of microbial proteinase inhibitors in murine dystrophy.
Enomoto A; Bradley WG
Arch Neurol; 1977 Dec; 34(12):771-3. PubMed ID: 337944
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of progressive muscular dystrophy in Okinawa, Japan. Classification with molecular biological techniques.
Nakagawa M; Nakahara K; Yoshidome H; Suehara M; Higuchi I; Fujiyama J; Nakamura A; Kubota R; Takenaga S; Arahata K
Neuroepidemiology; 1991; 10(4):185-91. PubMed ID: 1745328
[TBL] [Abstract][Full Text] [Related]
12. The disposition of loxistatin and metabolites in normal and dystrophic hamsters.
Fukushima K; Kohno Y; Osabe W; Suwa T; Satoh T
Xenobiotica; 1991 Jan; 21(1):23-31. PubMed ID: 2003364
[TBL] [Abstract][Full Text] [Related]
13. Intellectual function in Duchenne muscular dystrophy: the influence of penicillamine.
Buchanan DC; Roelofs RI; White DK; Saavedra de Arango G
Arch Phys Med Rehabil; 1981 Dec; 62(12):623-5. PubMed ID: 7032457
[TBL] [Abstract][Full Text] [Related]
14. Clinical trial network for the promotion of clinical research for rare diseases in Japan: muscular dystrophy clinical trial network.
Shimizu R; Ogata K; Tamaura A; Kimura E; Ohata M; Takeshita E; Nakamura H; Takeda S; Komaki H
BMC Health Serv Res; 2016 Jul; 16():241. PubMed ID: 27401940
[TBL] [Abstract][Full Text] [Related]
15. The relationships between enzyme inhibitors and function of mammalian cells.
Aoyagi T; Umezawa H
Acta Biol Med Ger; 1981; 40(10-11):1523-9. PubMed ID: 7044007
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic trial with protease inhibitor (leupeptin) in chicken muscular dystrophy. A histologic and histochemical study.
Nonaka I; Ishiura S; Takagi A; Sugita H
Acta Neuropathol; 1982; 58(4):279-85. PubMed ID: 7158305
[TBL] [Abstract][Full Text] [Related]
17. Limited benefit to genetically dystrophic chickens from a synthetic proteinase inhibitor: Ep475.
Hudecki MS; Pollina CM; Heffner RR
J Neurol Sci; 1983 Jul; 60(1):55-66. PubMed ID: 6875613
[TBL] [Abstract][Full Text] [Related]
18. [Double-blind study of the efficacy of an antiserotoninergic drug, pizotifen, in Duchenne's muscular dystrophy].
Steru D; Paclet JP; Barthelet G; Gailliard G; Piton A; Monchartre E; Roche R; Galli J; Lancrenon S; Fermanian J
Arch Fr Pediatr; 1987; 44(6):461-5. PubMed ID: 3619586
[TBL] [Abstract][Full Text] [Related]
19. Progressive muscular dystrophy in Denmark. Natural history, prevalence and incidence.
Leth A; Wulff K; Corfitsen M; Elmgreen J
Acta Paediatr Scand; 1985 Nov; 74(6):881-5. PubMed ID: 4090963
[TBL] [Abstract][Full Text] [Related]
20. Ineffectiveness of allopurinol in Duchenne muscular dystrophy.
Doriguzzi C; Bertolotto A; Ganzit GP; Mongini T; Palmucci L
Muscle Nerve; 1981; 4(2):176-8. PubMed ID: 7010155
[No Abstract] [Full Text] [Related]
[Next] [New Search]
